Xarelto lawsuits have been consolidated for multidistrict litigation, the U.S. Judicial Panel on Multidistrict Litigation has decided. According to court documents, the panel ruled that the almost two dozen lawsuits against Bayer and Johnson & Johnson subsidiary Janssen, which designed and manufactured the blood thinner, will be consolidated in the U.S. District Court for the Eastern District of Louisiana. Multidistrict litigation (MDL) is a procedural tool that consolidates complex cases so they are managed by one court. The panel’s decision comes after lawsuits were filed alleging the drug companies minimized the risk of bleeding associated with Xarelto. Bloomberg News reported in December of 2014 that consumers contend 65 deaths have been linked to bleeding caused by the drug, according to court filings. While Xarelto is used to reduce the risk of blood clots and strokes, the drug comes with an increased risk of uncontrolled bleeding events. Lawsuits against the companies behind Xarelto allege that they failed to warn about this risk. They further allege that the drug was marketed as superior to Coumadin (a blood thinner around since the 1950s) when, in fact, the efficacy of Xarelto when taken as marketed and prescribed has been questioned. Plaintiffs in the Xarelto ligation also contend the drug was not properly tested before it was approved by the U.S. Food and Drug Administration for the U.S. market in 2011. The lawyers at Salvi, Schostok & Pritchard are investigating Xarelto cases. Contact us at 1-800-Salvi-Law to speak directly with an experienced product liability attorney if you or a loved one has suffered harm after taking Xarelto. We will make sure you have a full understanding of your legal rights and options available for your case.